scholarly journals Korrektsiya arterial'noy gipertonii u bol'nykh sakharnym diabetom 2 tipa: fokus na zhestkost' arteriy

2011 ◽  
Vol 8 (2) ◽  
pp. 19-25
Author(s):  
Olga Konstantinovna Vikulova
Keyword(s):  
Metabolic Syndrome ◽  
Arterial Stiffness ◽  
Ace Inhibitor ◽  
Antihypertensive Effect ◽  
Cardiovascular Complications ◽  
Organ Protection ◽  
Factors Associated ◽  
Pathogenic Factors ◽  
Patients With Diabetes ◽  
Complications And Mortality

Elevation of the arterial stiffness is one of the important pathogenic factors associated with a high risk of cardiovascular complications and mortality rate in patients with diabetes and metabolic syndrome. Correction of the arterial stiffness has a great value for decrease of the risk of atherosclerosis progress and organ protection. Therapy with ACE inhibitor ramipril provides not only high antihypertensive effect but also significant improvement of parameters of the arterial stiffness which indicates an additional vasoprotective effect of the drug.

scholarly journals Vascular stiffness in patients with arterial hypertension: possible antihypertensive therapy

2016 ◽  
Vol 13 (2) ◽  
pp. 17-23
Author(s):  
O D Ostroumova ◽  
A I Kochetkov ◽  
M V Lopukhina
Keyword(s):  
Blood Pressure ◽  
Arterial Stiffness ◽  
Pulse Wave Velocity ◽  
Pulse Wave ◽  
Antihypertensive Drugs ◽  
Vascular Wall ◽  
Cardiovascular Complications ◽  
Increased Risk ◽  
Pharmacokinetic Properties ◽  
Complications And Mortality

The article discusses the factors that increase the arterial stiffness: the blood pressure, atherosclerosis, smoking, diabetes, age. Given evidence that pulse wave velocity and a number of other indicators that reflect the state of the vascular wall, are markers for increased risk of cardiovascular complications and mortality. The influence of antihypertensive drugs of different groups on the stiffness of the vascular wall, with particular attention paid to the effects of drugs from group of diuretics. We discuss possible mechanisms of the influence of indapamide retard on the elastic properties of vessels. It is emphasized that the influence on the stiffness of the arteries of different antigipertenzivny medicines, even belong to the same class, is different, due to differences in pharmacokinetic properties.

scholarly journals COMBINATION THERAPY IN THE MANAGEMENT OF ARTERIAL HYPERTENSION: EFFECTIVENESS OF THE LERCANIDIPINE AND ENALAPRIL COMBINATION

2013 ◽  
Vol 12 (5) ◽  
pp. 75-80
Author(s):  
L. O. Minushkina
Keyword(s):  
Combination Therapy ◽  
Arterial Hypertension ◽  
Marked Reduction ◽  
Ace Inhibitor ◽  
Fixed Dose ◽  
Therapeutic Effects ◽  
Organ Protection ◽  
Vascular Selectivity ◽  
Patients With Diabetes ◽  
Dose Combination

This review presents the evidence on the benefits of fixed-dose combination therapy for arterial hypertension management. The focus is on the combination of a third-generation dihydropyridine calcium antagonist lercanidipine and an ACE inhibitor enalapril. Lercanidipine is characterised by high vascular selectivity and lipophilicity, good antihypertensive effectiveness, and prolonged, gradually developing therapeutic effects. Literature data on the effectiveness of the lercanidipine-enalapril combination are presented. This combination facilitates a marked reduction in blood pressure levels, which is particularly relevant for elderly patients and patients with diabetes mellitus or obesity. The combination of pharmacologic effects of lercanidipine and enalapril provides additional benefits in terms of organ protection and reduction of adverse effects of the antihypertensive treatment. 

scholarly journals Whether all ACE inhibitors enzyme are identical? Focus on zofenopril.

2009 ◽  
Vol 6 (3) ◽  
pp. 4-7
Author(s):  
Lyudmila Gennadievna Ratova ◽  
Irina Evgen'evna Chazova
Keyword(s):  
Cardiovascular Disease ◽  
Clinical Trials ◽  
Mortality Risk ◽  
Ace Inhibitors ◽  
Randomized Clinical Trials ◽  
Ace Inhibitor ◽  
Cardiovascular Complications ◽  
Complications And Mortality

The results of randomized clinical trials were analyzed. The therapy with an ACE inhibitor zofenopril in patients with cardiovascular disease resulted to reduction of cardiovascular complications and mortality risk. Zofenopril was safe and well-tolerated patients. Ongoing zofenopril trials are also reviewed.

Abstract 410: Combination Therapy With Lercanidipine and Enalapril Improves Wave Reflection in Hypertensive Patients With Metabolic Sindrome

Hypertension ◽  
2013 ◽  
Vol 62 (suppl_1) ◽  
Author(s):  
Lorenzo Ghiadoni ◽  
Rosa Maria Bruno ◽  
Francesco Stea ◽  
Giulia Cartoni ◽  
Agostino Virdis ◽  
...  
Keyword(s):  
Metabolic Syndrome ◽  
Arterial Stiffness ◽  
Combination Therapy ◽  
Ace Inhibitor ◽  
Wave Reflection ◽  
Augmentation Index ◽  
Applanation Tonometry ◽  
Hypertensive Patients ◽  
Parallel Group ◽  
Significant Difference

Arterial stiffness and wave reflection are independent predictors of cardiovascular events. This study compared the effect on arterial stiffness and wave reflection of a combination therapy with an ACE-inhibitor plus calcium channel blocker or thiazide diuretic in essential hypertensive patients with metabolic syndrome uncontrolled by ACE-inhibitor monotherapy. In a multicenter randomized, open, parallel group study, 76 hypertensive patients with metabolic syndrome, after 4 weeks run-in with Enalapril 20 mg, were randomized to a combination therapy with Lercanidipine (LER, 10-20 mg) or Hydrochlorothiazide (HCT, 12,5-25 mg) for 6 months. Applanation tonometry was used to measure aortic stiffness (carotid to femoral pulse wave velocity, PWV), central blood pressure (BP) and augmentation index (AI), a marker of wave reflection. At screening, office BP was 153±4/95±2 mmHg in both groups. After run in, BP was 139±18/84±12 and 142±17/84±10 mmHg, in the LER and HCT groups, respectively, and after 6-month it was 134±15/79±9 mmHg in the LER group and 134±14/79±10 mmHg in the HCT group. No significant difference between the two groups was observed. Central BP values had a similar behavior (6 months: LER 120±13/80±9 mmHg; HCT 122±13/79±9 mmHg). PWV was similar at baseline and was equally reduced by the two treatments (LER from 8.6±1.5 to 8.1±1.3 m/s; HCT from 8.5±1.2 to 8.2±1.0 m/s). Finally, both drugs reduced AI, but this reduction resulted significantly greater in LER than in HCT arm (LER from 26.8±10.9 to 20.6±9.1%; HCT from 28.2±9.0 to 24.7±8.7%). In conclusion, the addition of LER caused the same PWV reduction as compared to HCT but greater reduction in AI in hypertensive patients with metabolic syndrome not controlled with Enalapril alone. These results indicate a positive effect of the combination with LER on wave reflection, suggesting a potential role for cardiovascular protection.

scholarly journals Trends in Cardiovascular Complications and Mortality among Patients with Diabetes in South Korea

2021 ◽  
Vol 45 (2) ◽  
pp. 283
Author(s):  
Jung Hwan Park ◽  
Kyoung Hwa Ha ◽  
Bo Yeon Kim ◽  
Jae Hyuk Lee ◽  
Dae Jung Kim
Keyword(s):  
South Korea ◽  
Cardiovascular Complications ◽  
Patients With Diabetes ◽  
Complications And Mortality

Risk Factors Associated With Hyperuricemia in Patients with Diabetes Type 2: About 190 Cases

2020 ◽  
Vol 2 (1) ◽  
pp. 12-16
Author(s):  
Fennoun H ◽  
Haraj NE ◽  
El Aziz S ◽  
Bensbaa S ◽  
Chadli A
Keyword(s):  
Type 2 Diabetes ◽  
Heart Disease ◽  
Glycemic Control ◽  
Ischemic Heart Disease ◽  
Diabetes Type 2 ◽  
Diabetes Type ◽  
Ischemic Heart ◽  
Factors Associated ◽  
Patients With Diabetes

Introduction: Hyperuricemia is common Type 2 diabetes at very high cardiovascular risk. Objective: Evaluate the relationship between hyperuricemia and diabetes type 2, and determine its predictive factors in this population. Patients and Methods: Retrospective study cross including 190 patients with diabetes type 2 hospitalized Service of Endocrinology of CHU Ibn Rushd Casablanca from January 2015 to December 2017. Hyperuricemia was defined as a serum uric acid concentration> 70 mg/L (men) and> 60 mg/L (women). The variables studied were the anthropometric measurements), cardiovascular factors (tobacco, hypertension, dyslipidemia), and degenerative complications (retinopathy, neuropathy, kidney failure, ischemic heart disease). The analyzes were performed by SPSS software. Results: Hyperuricemia was found in 26.5% of patients with a female predominance (76%), an average age of 55.9 years, and an average age of 12.4ans diabetes. The glycemic control was found in 84.6% of cases with mean glycated hemoglobin 8.6%. Factors associated al hyperuricemia were the blood pressure in 86% (p <0.05), dyslipidemia in 76.3% of cases (p <0.001) with hypertriglyceridemia in 48.3% of cases (p <0.02), and a hypoHDLémie 28% (p <0.001). The age, obesity, smoking, and glycemic control were associated significantly n al hyperuricemia. The research of degenerative complications of hyperuricemia has objectified renal impairment (GFR between 15 and 60ml / min) chez47% (p <0.001), it was kind of moderate in 35.8% (p <0.01) and severe in 5.1% (p <0.02), ischemic heart disease was found in 34% of cases (p <0.01). Conclusion: In our study, hyperuricemia in type 2 diabetes is common in female patients, especially with hypertension, dyslipidemia, and renal failure. Other factors such as age, obesity, smoking is not associated with hyperuricemia in type 2 diabetics.

MALIGNANT TUMORS ASSOCIATED WITH METABOLIC SYNDROME: THE EXPRESSION PROFILE OF THE TRANSCRIPTIONAL AND GROWTH FACTORS

2017 ◽  
Vol 63 (6) ◽  
pp. 817-823
Author(s):  
Natalya Yunusova ◽  
Irina Kondakova ◽  
Sergey Afanasev ◽  
Larisa Kolomiets ◽  
Alena Chernyshova
Keyword(s):  
Quality Of Life ◽  
Metabolic Syndrome ◽  
Growth Factors ◽  
Cell Motility ◽  
Expression Profile ◽  
Malignant Tumors ◽  
Molecular Targets ◽  
Factors Associated ◽  
High Incidence

The study of the pathogenetic features of malignant tumors associated with metabolic syndrome (MS) is relevant because of high incidence of these tumors. Investigations of the mechanisms of involvement of MS in the pathogenesis of cancer reasonably supplemented by the study of transcription and growth factors associated with energy imbalance of the cell and involved in proliferation, apoptosis, angiogenesis, cell motility and inflammation. More research is needed to identify the most promising molecular targets for therapy of malignant tumors associated with MS with a view to increasing the survival and quality of life of these patients.

Sign in / Sign up

Export Citation Format

Share Document